VML Health partners with ABC Global Alliance on Advanced Breast Cancer Report

#AWHONN strongly encourages nurses to work with women to develop individualized plans for breast cancer screening based on their age, health status, breast cancer risk assessment, and personal values. Read our NWH article on breast cancer screening. #BreastCancerAwarenessMonth https://lnkd.in/dcatryUU

#AWHONN strongly encourages nurses to work with women to develop individualized plans for breast cancer screening based on their age, health status, breast cancer risk assessment, and personal values. Read our NWH article on breast cancer screening. #BreastCancerAwarenessMonth https://lnkd.in/e9diK2C2

See what drives Dr. Giampaolo Bianchini, Head Breast Cancer Specialist at the San Raffaele Scientific Institute, as he discusses the latest topics shaping patient needs in breast cancer care, how international guideline adherence impacts treatment, and his biggest learnings from ESMO 2025. #ESMO2025

We are excited to announce the launch of the Tempus Gemini-Breast study, a non-interventional study evaluating minimal residual disease (MRD) through longitudinal ctDNA profiling in breast malignancies, during #BreastCancerAwarenessMonth. Congratulations to PIH Health Whittier Hospital, part of the Tempus TIME Network, for being the first site to open and enroll a patient, advancing research for those impacted by breast cancer. Learn more about the Gemini-Breast study here: https://lnkd.in/gEDi2JKk

#NEWS: New positive results in HER2-mutant non-small cell lung cancer (#NSCLC) have been published in the New England Journal of Medicine and presented at ESMO 2025 today. Patients with HER2-mutant NSCLC face limited treatment options and poor prognosis, highlighting an urgent need for more effective therapies. This milestone reflects our ongoing commitment to advancing cancer care where it is needed most. Learn more: https://www.nejm.org/ #OncologyInspired

October is Breast Cancer Awareness Month — a time not only to reflect on progress, but to reimagine what’s possible. In our latest blog, SimBioSys President & CEO Stacey Stevens challenges us to look beyond ribbons and reminders — toward a future where every decision in breast cancer care is guided by clarity, context, and individualized insight. With AI-powered tools now offering richer visualizations and deeper analytics, the way we understand and treat breast cancer is evolving — and so must our expectations. 🧠 Explore the perspective: https://lnkd.in/edX5zsHZ #Blog #BreastCancerAwareness #PrecisionOncology #AIinHealthcare #SurgicalInnovation #CancerCare #TumorSightViz #BCAM #SimBioSys

‎🎗️ #Breast_Cancer_Awareness_Month ‎🌍 Globally, breast cancer is the most common cancer among women and the second most common cancer overall. ‎📊 In 2022 alone, an estimated 2.3 million new cases and 670,000 deaths were reported worldwide (WHO) ، Ongoing research is essential to improve early diagnosis, and develop personalized, evidence-based therapies. ‎In this series, we’ll explore each major breast cancer subtype and its clinical management through the lens of current scientific advancements. ‎With deep appreciation to Dr. Nafisa Hassan Abdelhafiez , whose extensive input and expert review have been vital to this initiative.

Mammograms remain one of the most effective tools for detecting breast cancer early, when it’s most treatable. When breast cancer is found at a localized stage, the 5-year relative survival rate is about 99%, according to the American Cancer Society. This powerful statistic highlights a simple truth: early detection saves lives. Click here to read our latest blog article to learn more: https://bit.ly/4obIFTB -- #october #breastcancerawarenessmonth #breastcancerawareness #breastcancer #mammograms #earlydetection

Major advances in treatment and care have led to improved survival for many women with advanced breast cancer, new study finds. https://lnkd.in/eaZUCifP #MetastaticBreastCancer #AdvancedBreastCancer #BreastCancerSurvival #HER2Positive #HormoneReceptorPositive #TripleNegativeBreastCancer